Every claim below was checked against primary or peer-reviewed secondary sources before publication. One widely circulated claim — a purported 1943 Bayer letter offering "170 Reichsmark per woman" for Auschwitz drug trials — was deliberately left out. A 2019 forensic-archival investigation found no trace of it in the Bayer, Auschwitz, or IG Farben Nuremberg trial records. It is repeated constantly online. It does not appear here.1
The Authorization Chain
In The Pattern Behind the Pattern, this dossier laid out forensic and documentary evidence around the origin of SARS-CoV-2 — including a 2018 DARPA proposal, DEFUSE, that sought to insert human-compatible cleavage sites into bat coronaviruses. That article deliberately stayed inside its own evidentiary lane. This one asks the question that sits underneath it: when a pharmaceutical or chemical company's research crosses into territory a reasonable ethics board would refuse, what has historically stopped it? The documented answer, across a century and multiple continents, is almost never the company's own conscience. It is whatever authorization — legal, military, or regulatory — the state happens to grant or withhold at that moment. This is the chain, link by link, sourced.
1. A Chemist's Two Legacies
The pattern this article traces did not begin with a corporation. It began with one man, decades before IG Farben existed as a company.
The Man Who Fed the World and Armed Its Executioners
Fritz Haber, a Jewish-German chemist, invented the Haber-Bosch process for synthesizing ammonia from nitrogen — the single innovation credited with making artificial fertilizer possible, and with it feeding a share of the world's population historians estimate in the billions. The same man pioneered German chlorine-gas warfare in the First World War and developed Zyklon A, a cyanide-based pesticide later licensed through the company Degesch and reformulated into Zyklon B. Haber fled Germany in 1933 as the Nazis rose to power and died in exile in Switzerland in 1934. His own nieces, nephews, and extended family were murdered years later in Auschwitz's gas chambers, killed by a gas descended directly from his own research.2
2. IG Farben Buys a Government
IG Farben — Interessengemeinschaft Farbenindustrie AG — formed in 1925 from a merger of Bayer, BASF, Hoechst, Agfa, and others, becoming the largest chemical company on Earth. On 20 February 1933, three weeks after Hitler's appointment as chancellor, Hermann Göring and Hjalmar Schacht convened Germany's leading industrialists at a secret meeting. Hitler promised the elimination of trade unions and a massive rearmament program. An election fund for the NSDAP was created on the spot. IG Farben was its largest single donor.3
What the company received in return was not ideology — its leadership had previously been criticized by Nazi extremists as "internationalist" and employed numerous Jewish scientists and board members. What it received was economic: state-guaranteed purchase and import protection for its synthetic fuel and rubber (Buna) technologies, which were not commercially viable on the open market; an unlimited rearmament contract pipeline; and a disciplined, strike-free workforce once unions were banned.
IG Farben built a synthetic-rubber plant, Auschwitz III-Monowitz, directly adjacent to the concentration camp, using tens of thousands of forced laborers; an estimated 25,000 to 30,000 died there from exhaustion, starvation, and mistreatment. Degesch, a subsidiary roughly 42.5% owned by IG Farben, manufactured and supplied the Zyklon B used in the gas chambers of the extermination camps.4
The Company's Own Man Inside the Camps
Vetter served as a camp physician at Auschwitz, Dachau, Mauthausen-Gusen, and Gross-Rosen. As a paid retainer of IG Farben, he deliberately infected prisoners with typhus and tuberculosis and tested experimental drugs on them. He was convicted by an American military tribunal at the 1947 Mauthausen Trial and executed in February 1949 — one of the few individuals from this entire chain who faced a capital sentence.5
3. Nuremberg's Revolving Door
The IG Farben trial — one of the twelve subsequent Nuremberg proceedings — convicted several board members of slavery and mass murder. The sentences were short. What happened next is more instructive than the trial itself.
A Convicted War Criminal Chaired Bayer's Board Within a Decade
Ter Meer was sentenced to seven years at Nuremberg in 1948 for mass murder and enslavement. He was released in 1950 — and in 1956 was elected chairman of Bayer AG's supervisory board, a position he held until 1964.6
From the Auschwitz Buna Plant to the Thalidomide Advisory Board
Ambros was sentenced to eight years at Nuremberg in 1948 and released early in 1951. He was retained afterward as a consultant to the U.S. Army's chemical-weapons program and to Dow Chemical and W.R. Grace and Company — engaged in Germany, not resettled to the U.S. under Operation Paperclip itself, but drawing on the same Cold War calculus that drove Paperclip. Separately, he became chairman of the advisory board of Chemie Grünenthal — the company that developed and marketed thalidomide (Contergan), responsible for tens of thousands of severely malformed births worldwide between 1957 and 1961 — a position Ambros held until his death in 1990.7
4. The Nerve Gas, the Data, and a Second Deal on the Other Side of the World
IG Farben chemist Gerhard Schrader discovered the G-series nerve agents — Tabun, Sarin, and Soman — in the 1930s and '40s. When the U.S. Chemical Warfare Service learned how far ahead German chemical-weapons research had progressed, it moved to secure the scientists and the formulas, in Germany and via Operation Paperclip and its sister programs. Medical data harvested from camp experiments — on hypothermia, high-altitude exposure, and chemical-agent effects — was studied afterward by American aviation-medicine researchers, largely without acknowledging how it had been obtained.
The Same Deal, the Pacific Theater
Unit 731 conducted biological and chemical human experimentation — plague dispersal, frostbite, vivisection — on prisoners in occupied China from 1936 to 1945, killing several thousand directly and tens of thousands more in field releases. After Japan's surrender, the United States granted Ishii and his senior researchers full immunity from prosecution in exchange for their data, judged too valuable, and too unethical to replicate, to discard. Ishii was never arrested and died a free man in 1959; the immunity arrangement stayed classified until the 1990s.8 Same mechanism as Ambros — state interest in the data outweighing the crime behind it — on the opposite side of the planet.
5. MK-ULTRA: When the Supply Chain Needed a Domestic Source
In the 1950s, the CIA's MK-ULTRA program sought psychoactive compounds for interrogation and "mind control" research. Its initial LSD supply came directly from Sandoz, the Swiss firm where the compound had been discovered. When the CIA judged a foreign supply chain a security risk, it turned to the American firm Eli Lilly, which — with covert government backing — reverse-engineered LSD's synthesis so the agency would have an independent domestic source for research conducted on subjects who had not consented.
6. Agent Orange, and the Merger That Closed the Loop
During the Vietnam War, Dow Chemical and Monsanto were contracted to mass-produce Agent Orange, the defoliant used to strip Vietnamese jungle cover and destroy crops. Both companies knew the production process generated dioxin contamination; both continued fulfilling the military contract. In 2018, Bayer completed its acquisition of Monsanto — placing the corporate descendant of the company with the paid physician inside Auschwitz and the company that manufactured Agent Orange under the same roof.
7. The Moratorium
A Federal Pause on Engineering More Dangerous Viruses
The White House Office of Science and Technology Policy announced a funding pause on "gain-of-function" research reasonably anticipated to enhance the transmissibility or pathogenicity of influenza, MERS-CoV, and SARS-CoV in mammals via the respiratory route — covering federally funded work and requesting voluntary compliance even outside federal funding. The National Science Advisory Board for Biosecurity and the National Research Council were tasked with a formal risk-benefit review. It was not a blanket ban; agencies retained discretion to permit individual projects through internal review.9
The Pause Lifted — and What Happened Less Than a Year Later
Following the release of the White House OSTP's January 2017 policy guidance, the HHS "Framework for Guiding Funding Decisions about Proposed Research Involving Enhanced Potential Pandemic Pathogens" (P3CO) was published, and NIH formally lifted the three-year funding pause on 19 December 2017.10 In 2018 — the following year, under this newly reopened door — the DEFUSE proposal (DARPA solicitation HR00118S0017) sought funding to insert human-compatible cleavage sites into bat coronavirus spike proteins, with Vincent Munster of the Rocky Mountain Laboratories network as a proposed partner. DARPA rejected it, citing gain-of-function and dual-use risk specifically.11 The full documentary record on DEFUSE, its Rotterdam-network connections, and what followed is laid out in The Pattern Behind the Pattern.
8. Two Sets of Rules
The P3CO framework, whatever its limitations, was a documented multi-agency review structure applying to U.S.-funded enhanced-pathogen research. The equivalent structure for the specific category of research conducted at the Wuhan Institute of Virology did not exist in the same form.
A Lab Built by France, Then Locked Out
The WIV's BSL-4 laboratory began as a 2004 joint project with France, which supplied the facility's design, biosafety training, and much of its technology. Construction finished in January 2015; by 2017, French personnel had been phased out of the collaboration and cooperation had effectively ceased. A U.S. State Department cable from April 2018 recorded "grave concerns" about the lab's oversight and China's intentions for it.12
"An Actual Scandal"
Before 2020, Chinese research characterizing novel bat coronaviruses — the same category of virus SARS-CoV-2 belongs to — was routinely conducted at Biosafety Level 2 (BSL-2), a containment tier meant for moderately hazardous, already-endemic pathogens, even though SARS and MERS work itself required BSL-3 in the same period. Stanford bioengineer Michael Lin: "an actual scandal." China's National Health and Family Planning Commission held nominal regulatory authority, but specialized biosafety oversight and independent review did not scale with the pace at which China's biotechnology sector was expanding.13
9. Warp Speed's Open Secret
None of what follows is covert. It is a matter of public record — which is exactly the point: the military-pharmaceutical structure this article has traced through 1933, 1951, and 2018 did not go into hiding for 2020. It was announced under its own name.
A Four-Star General Ran the Logistics
Perna, previously head of U.S. Army Materiel Command, was named COO of Operation Warp Speed in 2020. The Department of Defense was, in its own public description, "a key partner in both the science and the logistics" of the program, providing program management and contracting expertise alongside HHS.14
The mRNA Platform's First Money Came From DARPA
Moderna received its first substantial outside funding — roughly $25 million — from DARPA in 2013, years before the company brought any product to market. The program's explicit stated purpose was protection against "emerging infectious diseases and engineered biological weapons." DARPA later credited its own investment with enabling the first coronavirus vaccine to reach human trials.15
The Legal Mechanism That Removed the Liability Brake
The HHS Secretary's March 2020 declaration under the Public Readiness and Emergency Preparedness Act granted vaccine manufacturers and distributors broad immunity from liability for death, injury, or other loss connected to COVID-19 countermeasures, with the sole exception of willful misconduct.16 This is not identical to the wartime state contracts that shielded IG Farben, or the Cold War pragmatism that freed Ambros early — but it is the same structural function: a legal mechanism, granted by the state, that removes the ordinary liability consequence that would otherwise discipline corporate risk-taking.
10. The Batches: A Documented Possibility, Not a Verdict
Four Countries, Same Signal — Cause Not Established
Four independent, peer-reviewed studies from the same core research group found statistically significant batch-to-batch variation in serious adverse event (SAE) rates for mRNA COVID-19 vaccines: Denmark (Schmeling et al., European Journal of Clinical Investigation, 2023, three distinct batch clusters, R²=0.68–0.89); the Czech Republic (Fürst et al., same journal, 2024, independent replication); Denmark-Sweden (Manniche et al., Medicina, 2024, cross-border correlation); and Germany (Manniche et al., International Journal of Risk & Safety in Medicine, 2026, a tenfold range in SAE rates between batch clusters — 2.2 to 22.8 per 1,000 doses).
This is a real, replicated finding — and it is not evidence of intentional design. A Dutch study using active medical-record surveillance across nearly 10 million vaccinations found no comparable batch effect, a divergence the authors attribute to methodology (active vs. passive surveillance) rather than contradiction. The plainest explanation for genuine batch variation is the one the underlying researchers themselves point to: manufacturing inconsistency under emergency-authorized, multi-site, compressed-timeline production — not a designed experiment. Whether the variation reflects that, or something else, remains an open question this dossier does not claim to resolve.
The mechanism repeats. Proof of intent, in this specific case, does not.
From a 1933 boardroom to a 2020 liability waiver, the throughline is not that pharmaceutical and chemical companies are uniquely malicious. It is that ethics has never been the load-bearing constraint on what these companies are permitted to do to human beings — state authorization has. Remove the authorization (Obama's 2014 pause, DARPA's rejection of DEFUSE) and the research stops or moves elsewhere. Grant it, or simply fail to build the equivalent oversight structure at all (Nuremberg's postwar pragmatism, China's BSL-2 gap, a 2020 liability shield), and it proceeds. Whether the documented batch variation in the COVID-19 vaccine rollout reflects intentional experimentation, as opposed to the same emergency-production chaos this article has traced through history, is not something the current evidence proves. What the historical record does establish, beyond dispute, is that the mechanism required for it to happen unchecked — a state-granted removal of the ordinary ethical and legal brake — was fully in place. That is the pattern this dossier can document. What is done with it is, as always, an open question.
Sources
- Aly, Herbst-Irmer & Schmidt, "No Proof Found of Anesthesia Involvement in Medical Misconduct During the Nazi Period," Anaesthesia Critical Care & Pain Medicine, 2019, PMID 31400833 — investigation finding no corroborating record of the alleged 1943 Bayer letters in Bayer, Auschwitz, or IG Farben Nuremberg trial archives.
- USHMM Holocaust Encyclopedia, "Bayer"; Fritz Haber, Encyclopedia Britannica and Nobel Prize biographical archive.
- Borkin, J. The Crime and Punishment of I.G. Farben, Free Press, 1978; USHMM Holocaust Encyclopedia, "Bayer."
- USHMM Holocaust Encyclopedia, "Bayer"; IG Farben Trial record, Nuremberg Military Tribunals, Case VI.
- Wikipedia/military-history archival summary of the 1947 Mauthausen Trial record; Auschwitz-Birkenau Memorial and Museum, "Other Doctor-Perpetrators."
- Fritz ter Meer, Nuremberg IG Farben Trial judgment, 1948; Bayer AG corporate history archive, 1945–1964.
- Otto Ambros, Nuremberg IG Farben Trial judgment, 1948; Grünenthal corporate history record; Newsweek, "The Nazis and Thalidomide: The Worst Drug Scandal of All Time."
- Historycollection.com and EBSCO Research Starters, "Unit 731"; U.S. National Archives declassified immunity-deal record (released 1990s).
- White House Office of Science and Technology Policy / U.S. Government, "U.S. Government Gain-of-Function Deliberative Process and Research Funding Pause on Selected Gain-of-Function Research Involving Influenza, MERS, and SARS Viruses," 17 October 2014.
- HHS, "P3CO Framework," January 2017; NIH, "NIH Lifts Funding Pause on Gain-of-Function Research," 19 December 2017; Notice NOT-OD-17-071.
- DEFUSE proposal (DARPA HR00118S0017, 2018), reported by The Intercept, 23 September 2021 — see full record in The Pattern Behind the Pattern.
- State Department cable, April 2018, reported by The Daily Signal, 28 July 2021; Gilles Demaneuf, "BSL-4 laboratories in China," DRASTIC research summary.
- MIT Technology Review, "Inside the risky bat-virus engineering that links America to Wuhan," 29 June 2021.
- StatNews, "New document reveals scope and structure of Operation Warp Speed," 28 September 2020; U.S. Department of Defense public program description.
- DARPA/Moderna Therapeutics grant announcement, PRNewswire, 2013; news.modernatx.com, "DARPA Awards Moderna Therapeutics a Grant for up to $25 Million," 2013.
- HHS Secretary PREP Act Declaration for medical countermeasures against COVID-19, effective 4 February 2020 (amended March 2020); phe.gov, "PREP Act Immunity from Liability for COVID-19 Vaccinators."
The Reference
500 botanicals — each with documented mechanisms, dosages, and synergy protocols. The complete reference for sovereign health practice.
The 500 Most Powerful Botanicals →